QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
QGEN(NYSE:QGEN) VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections. The QIAstat-Dx system now offers CE-IVDR certified panels for respiratory, gastrointestinal and CNS infections that help clinicians d
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
QGEN(NYSE:QGEN) GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide. The new system, which received clearance from the U.S. Food and Drug Administration (FDA), is designed to meet the needs of hospitals and reference laboratories seeking highly automat
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
QGENVENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced solid results for Q2 2025 that exceeded the outlook, and increased the full-year 2025 outlook for net sales growth while reaffirming the adjusted diluted earnings per share (EPS) target that was raised earlier in the year. Net sales rose 7% to $534 million compared to Q2 2024, with 6% growth at constant exchange rates (CER) exceeding the outlook for at least 5% CER growth. Core sales, wh
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
QGENVENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. GENCURIX is the first development partner under QIAGEN’s QIAcuityDx Partnering Program. This important advancement marks a significant step towards establishing a broad menu of in vitro diagnostic (IVD) as
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QGENVENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofi
Reported Earlier, Tracer Biotechnologies And QIAGEN Partner To Co-Develop Blood-Based MRD Assays For Solid Tumors On QIAcuity Digital PCR Platform
QGENQIAGEN Expands Oncology Diagnostics Portfolio With Two Strategic Partnerships To Advance Use Of MRD Testing In Clinical Trials To Support Pharma Co-Development Projects For Companion Diagnostics
QGENForesight Diagnostics Partners With QIAGEN To Develop, Commercialize Kit-Based Version Of CLARITY Assay For Lymphoma
QGENQIAGEN Announces New Commercial Partnership And Co-Marketing Agreement With ID Solutions To Expand Availability Of dPCR Assays For Oncology Research Applications
QGENQIAGEN To Acquire GENOOX For $70M
QGENQIAGEN To Elect Stephen H. Rusckowski As Chairman; To Succeed Lawrence A. Rosen
QGENQiagen FY2025 Reaffirms EPS Of $2.35 CER Vs $2.49 Est
QGENQIAGEN At Annual General Meeting Proposes To Introduce A Dividend As Expansion Of Capital Allocation Strategy, Also Seek Authorization For A New $500M Share Repurchase
QGENQiagen Q1 Adj. EPS $0.55 Misses $0.56 Estimate, Sales $483.00M Miss $507.25M Estimate
QGENQIAGEN To Propose Initiation Of Annual Cash Dividend Consisting Of $0.25 Per Ordinary Share At Next Annual General Meeting
QGENQIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control
QGENBaird Maintains Neutral on Qiagen, Raises Price Target to $43
QGENWatching Qiagen N.V.; Hearing Fivespan Is Said To Build Stake In Life Sciences Group Qiagen
QGENQIAGEN To Launch Three New Sample Prep Instruments By 2026, Expanding Automation From Low To High Throughput Labs
QGENQIAGEN's QCI Interpret One Selected By Royal Marsden NHS Foundation Trust To expand Marsden360 Liquid Biopsy Service For ESR1 Testing For Breast Cancer Patients
QGENReported Sunday, QIAGEN Preliminary Q1 2025 Revenue ~$483M And Expects Adj. EPS Of At least $0.55 (Vs. $0.56 Est.); Raised 2025 EPS Target To ~$2.35 (Vs. $2.48 Est.) From Prior $2.28
QGENRedburn Atlantic Downgrades Qiagen to Neutral
QGENQIAGEN's QIAprep Plasmodium Kit Supports Global Malaria Efforts With Enhanced Detection Of Mixed Infections And Parasite Strains
QGENZymo Research Says Court Denied QIAGEN GmbH's Partial Motion To Dismiss And In The Alternative, To Stay Certain Counterclaims Brought By Zymo
QGENQIAGEN Announced That The U.S. Food And Drug Administration (FDA) Has Cleared The QIAstat-Dx Gastrointestinal Panel 2 Mini B For Clinical Use, Further Strengthening Its Syndromic Testing Portfolio In The United States
QGENQIAGEN Files Lawsuit To Protect QuantiFERON Technology Amid Tuberculosis Testing Patent Dispute
QGENBaird Downgrades Qiagen to Neutral, Lowers Price Target to $42
QGENQiagen Said Sunday, It Will Return ~$300M To Shareholders Through A Synthetic Share Repurchase
QGENReported Earlier, QIAGEN Gains FDA Clearance For QIAstat-Dx Mini Gastrointestinal Panel, Supporting Year-Round Outpatient Care
QGENSyros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022
QGENQIAGEN Reaffirms FY24 Sales Of At Least $1.985B Vs $1.98B Est.; Increases EPS Guidance From $2.10 CER To At Least $2.19 CER Vs $2.15 Est.
QGENQiagen Q3 Adj $0.57 Beats $0.54 Estimate, Sales $502.00M Beat $491.75M Estimate
QGENQIAGEN Gains FDA Clearance For Rapid QIAstat-Dx Meningitis/Encephalitis Panel, Boosting Emergency Diagnostics
QGENNeuron23 and QIAGEN Announced Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug; Terms Not Disclosed
QGENQIAGEN Continues To Update Its Range Of Automation Solutions With The Launch Of High-sensitive Capillary Electrophoresis Instrument Qiaxcel Connect
QGEN